INTRODUCTION
Good glycemic control is a cornerstone of prevention of long-term diabetic complications and reduces mortality in patients with type 2 diabetes (T2D) [1] [2] [3] . Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase-4 inhibitors (DPP-4is), are based on the intestinal hormone GLP-1 and lead to improved glycemic control and have a beneficial weight effect in patients with T2D [4] .
Liraglutide is a once-daily human GLP-1RA approved in over 100 countries worldwide for the treatment of adults with T2D by once-daily subcutaneous administration [5] . In the European Union (EU)/Sweden, liraglutide at doses up to 1.8 mg is indicated (approved in January 2010) for treatment of adults with T2D to achieve glycemic control in combination with oral glucose-lowering drugs when these, together with diet and exercise, provide inadequate glycemic control. In April 2014, liraglutide in T2D was approved in EU/Sweden for use in combination with basal insulin.
Sitagliptin, a DPP-4i approved for use in Sweden in June 2007, both as monotherapy and in combination with other oral glucose-lowering drugs and insulin for the treatment of T2D, has been shown to improve glycemic control in patients with T2D in several clinical trials [6, 7] . Moreover, sitagliptin is currently the most commonly prescribed DPP-4i in Sweden.
Data from clinical trials demonstrated that liraglutide was superior to sitagliptin in terms of reducing both glycated hemoglobin (HbA1c) and body weight in patients with T2D [8, 9] .
Randomized controlled trials (RCTs) are the gold standard for evaluating efficacy and safety of therapeutic interventions [10] , but regulatory agencies and payers worldwide require assurance that RCT findings translate into clinical benefits in the broader patient populations of clinical practice. Healthcare providers, moreover, increasingly look for real-world clinical evidence that new therapies provide better outcomes and/or greater value than existing standards of care [11] .
The primary objective of this study was to assess the effectiveness of liraglutide in control of glycemia and body weight in clinical practice in Sweden. The secondary objective was to compare the effectiveness of liraglutide vs sitagliptin on glycemic control and body-weight reduction. To reduce the possible confounding effect on comparison of the two treatments by different baseline patient characteristics, which naturally vary more in observational studies than in randomized trials, propensity score-matching (PSM) was applied.
METHODS

Study Design and Data Extraction
This non-interventional, retrospective study was conducted between February 2014 and September 2014 where data from patients with T2D were collected from primary care centers (PCCs) and national healthcare registries in Sweden. Fifty-three PCCs were selected from a large geographical area of Sweden, representing *5-6% of the Swedish population. Data were extracted from electronic medical records (EMRs) held by PCCs using the Pygargus Customised eXtraction Program, CXP 3.0 (Pygargus; Stockholm, Sweden), a validated data-extraction tool [12] . Primary care medical records including laboratory measurements were linked with data from the national patient registry, national prescription registry, and national LISA (longitudinal integration database for health insurance and labor market studies) database kept at Statistics Sweden, for 2010-2013. Data on diabetes and comorbidities were also collected from the EMRs from 1996 onwards if available for each patient. 
Patients
Outcome Measures
Outcomes data were measured *180 days after index date and compared with data at or before index date (i.e. baseline, which was the period of 90 days before index date and 6 days thereafter, always choosing the observation closest to index date). Similar endpoints were used in both stages of the study (Table S1 ). Information on prescribed doses of liraglutide or sitagliptin was collected for all patients, and adherence to prescribed therapy was calculated for each patient and then summarized by treatment group. Adherence to therapy during the study period was determined using the medication possession ratio (MPR) (adherence threshold; C80%).
Statistical Analyses
A feasibility assessment was conducted at 10 PCCs to determine sample size for the present Four pre-planned sensitivity analyses were undertaken to investigate the robustness relating to the primary endpoint in stage 2. In the analyses, variables were incorporated singly into the matching process in a cumulative approach (analysis #1); each variable was added into the matching procedure and then removed in turn until all variables had been examined (analysis #2), and the propensity scores were divided into quartiles after matching (analysis #3). The final sensitivity analysis was conducted for all patients (analysis #4).
Compliance with Ethics Guidelines
The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices. Study approval was obtained from the Ethical Review Board in Stockholm, Sweden, and approval for access to EMRs from individual PCCs. National data-protection regulations were observed throughout, but patient-informed consent was not required due to the de-identified nature of collected data. The study is registered at ClinicalTrials.gov (NCT02077946).
RESULTS
Patient Disposition and Treatment
In total, data were extracted from EMRs for 3676 patients ( Fig. 1 ). Of these, 1155 patients were prescribed liraglutide (1.2 mg prescribed for 89% of patients) and 2521 were prescribed sitagliptin (100 mg prescribed for 95% of patients) ( Figure S1 ). A total of 402 patients prescribed liraglutide (88% of patients with MPR C80%) were included in stage 1.
In the liraglutide group, mean insulin dose for all patients treated with insulin before 63.3% vs 52.9%, respectively (P = 0.038)] due to the exclusion of patients with a change in insulin dose after index date. Before PSM and using sitagliptin as a reference, patients treated with liraglutide received their first diabetes diagnosis at a younger age, were younger, heavier, and had a higher BMI (Table 1) .
Furthermore, liraglutide-treated patients had a greater disease severity, as evidenced by a higher baseline HbA1c and a greater number of prescriptions of insulin in the 2 years before index date. Sitagliptintreated patients were often sulfonylurea (SU) users before index date [mean (standard deviation) prescriptions/patient/year 0.9 ± 1.8 (Table 2) . However, no significant effects were observed on LDL-cholesterol, HDL-cholesterol, triglycerides, creatinine or diastolic BP (Table 2) . Change from baseline in
Creatinine (mmol/L) After 180 days' treatment, 52.9% of patients receiving liraglutide achieved C1.0% (C10.9 mmol/mol) reduction in HbA1c vs 33.5% of patients treated with sitagliptin (P = 0.0002) (Fig. 2) . Results from three of the pre-specified sensitivity analyses showed similar results. In sensitivity analysis #3, where the population was divided into quartiles based on the propensity score value, only the highest quartile demonstrated significance. Patients in this quartile are characterized by being older and using less insulin.
In total, 71.1% of patients receiving liraglutide achieved the HbA1c target of \7.0% (Fig. 3) . Consequently, a significantly greater proportion of the liraglutide group than the sitagliptin group achieved C3.0% reduction in baseline body weight (51.6% vs 26.0%, respectively) and the composite endpoint based on NICE guidelines for liraglutide Fig. 2 Patients achieving the primary endpoint (C1.0% reduction in HbA1c), a reduction of C3.0% of initial body-weight, and fulfilling NICE criteria (for GLP-1RA treatment) (composite endpoint-a reduction C1.0% in HbA1c and C3.0% of initial body-weight) after 180 days of treatment. Data are for cohorts after PSM and after the exclusion of patients with a change in insulin dose during the treatment period. Proportions are calculated from patients with available data. GLP-1RA glucagon-like peptide-1 receptor agonist, HbA1c glycated hemoglobin, n number of patients, NICE National Institute for Health and Care Excellence, PSM propensity score matching Of those that had an increase in insulin dose, mean changes in body weight at the end of treatment were -1.1 vs 0.4 kg in the liraglutide and sitagliptin groups, respectively (P = 0.0446).
DISCUSSION
In the current study, more than one-third of patients treated with liraglutide achieved the goal of C1.0% (C10.9 mmol/mol) reduction in HbA1c. Furthermore, over half of patients receiving liraglutide achieved the HbA1c target of \7.0% (\53.0 mmol/mol) and there were greater reductions in HbA1c and body weight in patients receiving liraglutide than in those receiving sitagliptin.
Using a retrospective cohort study design allowed for collection and analysis of readily available data from EMRs, and the application of PSM limits the effects of confounding inherent in the design. The results from this study may be considered representative of the national profile of patients with T2D in Sweden, in part due to availability of data up to as recently as May 2014 and the multicenter design. However, due to the procedure of PSM and the observational nature of this study, selection bias cannot be excluded.
Additionally, the lack of safety/tolerability evaluation is a limitation of the study as it does not provide a full overview of the benefit/ risk profile of the drugs. In the present study, a similar proportion of the liraglutide group and the sitagliptin group were excluded. However, there was a noticeable difference between treatment groups in the proportion of patients previously treated with GLP-1RAs and DPP-4is (higher in the sitagliptin group). This finding may, in part, be explained by the higher age of the patients receiving sitagliptin and the fact that more patients were on insulin before index date in the liraglutide group, pointing toward a more severe disease cause in patients treated with liraglutide.
As intended for observational studies, the inclusion and exclusion criteria used in the current study were not as strict as those of clinical trials. Therefore, the normal clinical practice and the prescribing habits of physicians in Sweden could be investigated. Results generated before applying PSM demonstrated that clinicians in Sweden elect to prescribe liraglutide to patients with T2D who are younger and heavier with a greater disease severity. This is comparable with recent findings from a retrospective study from the UK [14] . In the current study, patients in the liraglutide group had a higher mean baseline body weight than those in the sitagliptin group.
Therefore, physicians appear not to select SUs for patients in the liraglutide group to prevent further weight gain, which is a known side-effect with SU treatment [15] . After Recently, an RCT showed beneficial effects of liraglutide in patients with T2D treated with multiple daily insulin injections [16] . Data from the post hoc analysis of the current study demonstrated that when physicians in Sweden added liraglutide to basal insulin, they tended to reduce the insulin dose. As the use of basal insulin with liraglutide was considered 'off-label' at this time, it is possible that many physicians reduced the insulin dose more than was necessary due to safety concerns. Also noteworthy in the study, the likelihood that a patient adhered to the treatment during RCTs [18] . The mean change in body weight from baseline after 180 days' treatment reported with liraglutide in the current study was similar to previous findings from another real-world study (-3.8 kg [14] ) and a recent RCT (-4.5 kg [27] 
